VIRAZID™

Ribavirin

Effective therapy for bronchiolitis due to RSV



Now you can treat the infection Not just the symptoms

Prescribing Information ▼

Indications
Virazid is indicated in the treatment of infants and children with severe respiratory syncytial virus bronchiolitis.

Dosage
Treatment is carried out using a small particle aerosol generator (SPAG) for 12-18 hours per day for at least 3 and no more than 7 days. The concentration of ribavirin in the reservoir is 20mg/ml in the SPAG unit and the average concentration for a 7 hour period is 0.19mg/l of air.

Presentation
Virazid is a sterile lyophilised powder of ribavirin to be reconstituted for aerosol administration. Each 100ml glass vial contains 6g of ribavirin and, when reconstituted to the correct volume of 300ml with Water for Injections BP, will contain 20mg/ml ribavirin at a pH of approximately 5.5.

Contra-Indications
Ribavirin is contra-indicated in females who are or may become pregnant and it should be noted that ribavirin can be detected in human blood even four weeks after oral administration has ceased.

Precautions
In infants requiring assisted ventilation, Virazid should only be used when there is constant monitoring of both patients and equipment.

Side Effects
Several serious adverse events occurred in severely ill infants with life-threatening underlying disease many of whom required assisted ventilation. These events included worsening of respiratory status, bacterial pneumonia and pneumothorax. The role of ribavirin aerosol in these events has not been determined.
Anaemia has been reported with oral and intravenous administration but no such incidents have been reported with aerosol administration. Reticulocytosis has been reported with aerosol use.

Warnings
Precipitation of the drug in respiratory equipment and consequent accumulation of fluid in the tubing has caused difficulties for patients requiring assisted ventilation.
In infants requiring assisted ventilation Virazid should only be used when there is constant monitoring of both patients and equipment.
Directions for use during assisted ventilation are given in the SPAG manual which should be read carefully before such administration.

Full prescribing information is available upon request.

▼ Special reporting to the CSM required.

Basic NHS Price: 1 × 6g vial £195.
Product Licence Number : 4657/0004
Product Licence Holder : Viratek Inc. USA
Supplied By : Britannia Pharmaceuticals Ltd Forum House 41-51 Brighton Road Redhill, Surrey, RH1 6YS


Crescormon
helped him grow
Somatonorm
is helping him grow

NEW

Genotropin™

somatropin (rbe)

Kabi announce the introduction of the authentic sequence biosynthetic growth hormone, Genotropin (somatropin (rbe)).

Genotropin™ 4IU

Genotropin, available in 4IU vials, is structurally identical to naturally occurring growth hormone, and as such is the natural successor to Crescormon and Somatonorm.

Genotropin will help him grow Naturally

PRESCRIBING INFORMATION

Presentations A vial of sterile lyophilised powder containing 4IU somatropin (rbe) supplied with a 1 ml ampoule of Water for Injections for reconstitution. **Indications** The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. **Reconstitution** Add 1 ml of Water for Injections to the lyophilised powder in the vial and dissolve gently without shaking vigorously. **Dosage and Administration** Administer by subcutaneous or intramuscular injection. Generally a dose of 0.5 – 0.7 IU/kg body weight per week is recommended divided into six or seven subcutaneous injections. Alternatively two to three intramuscular injections can be given. **Contra-Indications** Only patients with unfused epiphyses should be treated. **Precautions** Patients with diabetes mellitus may require adjustment of their antidiabetic therapy. Patients treated with Genotropin should be regularly assessed by child growth specialists. If given subcutaneously, the injection site should be varied to prevent lipoatrophy. **Pregnancy and Lactation** In the event of pregnancy occurring during Genotropin therapy, treatment should be discontinued. No information is available as to whether peptide hormones pass into breast milk. **Side-Effects** A few children developed transient local skin reactions during clinical trials. Some patients develop antibodies to growth hormone although the frequency with Genotropin has been low in clinical trials. **Pharmaceutical Precautions** Store between 2 – 8°C and protect from light. Genotropin 4IU is for single dose use only. Reconstituted Genotropin 4IU may be stored for up to 24 hours in the refrigerator before use. **Legal Category** POM **Package Quantities** Combined pack containing one vial of somatropin (rbe) 4IU and one vial of Water for Injections or ten vials of somatropin (rbe) 4IU and ten vials of Water for Injections. **Product Licence Numbers** Genotropin 4IU PL 0022/0071 Water for Injections PL 0022/0082 **Product Authorisation Number** PA 187/32/1 **Price** NHS Price Genotropin 4IU £30.50 Genotropin 10× 4IU £305.00 **Product Licence and Product Authorisation Holders** KabiVitrum Ltd. KabiVitrum House. Riverside Way. Uxbridge. Middlesex. UB8 2YF. KabiVitrum. Cahill May Roberts Ltd. P.O. Box 1090 Chapelizod. Dublin 20. Further information is available on request from the Product Licence holder.

KABI

KV785 6/88

PANCREASE* Capsules deliver

PANCREATIN BP

the full dose of enzyme right to the site of digestion.

PANCREASE* – the only enteric coated microsphere preparation.

- Protected from gastric inactivation
- Improves nutritional status
- Effective in Cystic Fibrosis and Chronic Pancreatic Insufficiency.

PRESCRIBING INFORMATION – PANCREASE* Capsules

Presentation: Hard white gelatin capsules containing enteric coated beads of pancreatin BP. Each capsule has a protease activity of not less than 330 BP Units and amylase activity of not less than 2,900 BP Units and lipase activity of not less than 5,000 BP Units. **Uses:** Exocrine pancreatic enzyme deficiency. **Dosage and administration:** For adults and children 1 or 2 capsules during each meal and one capsule with snacks. To protect the enteric coating the beads should not be crushed or chewed. **Contra-indications, warnings, etc.** Hypersensitivity to pork protein. The safety of Pancrease* during pregnancy has not yet been established. Such use is not recommended. The most frequently reported adverse reactions to Pancrease* Capsules are gastrointestinal in nature. Contact of the beads with food having a pH higher than 5.5 can dissolve the protective enteric shell. **Pharmaceutical precautions:** Keep bottle tightly closed. Store at room temperature in a dry place. Do not refrigerate. **Legal category:** P. **Package Quantities:** Containers of 100 capsules. **Basic NHS Cost:** £15.98 (for 100 capsules). **Product Licence Number:** PL 76/129.

Cilag

Further information available from:
Cilag Limited,
Saunderton,
High Wycombe, Bucks. HP14 4HJ

Enteric coated granules for improved enzyme delivery in cystic fibrosis

creon®
pancreatin

- Capsule dissolves in stomach
- Granules unaffected by stomach acid
- Enzymes released in duodenum
- Mimics the normal digestive process

A predictable release for cystic fibrosis patients

PRESCRIBING INFORMATION: Presentation: Brown/yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase; 8,000 BP units of lipase; 210 BP units of protease. Available in packs of 100. Basic N.H.S. price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules should be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result. **Contra-indications, Warnings, etc.** Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. **Warnings:** Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely, cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar

Further information is available from:
Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281



Detailed descriptions of the symptoms and signs of common disorders of the eye together with **over 120 colour illustrations** make the *ABC of Eyes* an invaluable aid to diagnosis. Written by A R Elkington, senior lecturer and consultant ophthalmologist, University of Southampton, and P T Khaw, senior registrar in ophthalmology, Moorfields Eye Hospital, London, the book also provides guidance on when to refer to a specialist, and how urgently.

Busy general practitioners will find this a useful reference book for the surgery while for medical students, optometrists, and nurses (particularly ophthalmic nurses) it offers a consise practical introduction to ophthalmology.

Chapters include:

History and examination • Red eye • Eyelid and lacrimal disorders • Injuries to the eye • Cataracts • Refractive errors • The glaucomas • Squint • The eye and the nervous system.

Inland £9.95; Abroad £12.50; USA $21.00
BMA members:
Inland £8.95; Abroad £11.50; USA $19.00
including postage by air abroad

Please enclose payment with order
***or* send us full details of your**
ACCESS, VISA or AMERICAN EXPRESS
credit card.

ORDER FROM British Medical Journal, PO Box 295, London WC1H 9TE or any leading medical bookseller

IVAC IV Therapy. It's like having X-ray eyes





Unfortunately, the most common causes of IV complications are not always visible to the naked eye, so you have to trust the IV instrument to help you.

Imagine a blocked IV, the patient stops receiving critical medication, or imagine a vesicant solution, such as potassium which is being infused interstitially due to an infiltration.

You need to know about it fast. Fast enough to take corrective action before the patient is at risk.

IVAC instruments actually 'monitor' the IV site while they deliver the medication, to let you know what's happening fast and keep you better informed.

Fast warning of IV problems, consistent, accurate delivery and simple operation all helps take the risk out of IV therapy.

And unless you've got X-ray eyes IV therapy can really be like working in the dark.

Call us – Telephone (0256) 474455

NO ONE KNOWS MORE ABOUT IV CONTROL

A Lilly Medical Instrument Systems Company

IVAC*

*Mark owned by IVAC Corporation

IVAC, INTEC 2 BUILDINGS, WADE ROAD, BASINGSTOKE, HANTS RG24 0NE.

Published by British Medical Association, Tavistock Square, London WC1H 9JR, and printed in England by The Devonshire Press Ltd., Torquay

PRESCRIBING INFORMATION
HUMAN VELOSULIN® ▼ (Neutral Insulin Injection, human insulin (emp)). HUMAN INSULATARD® ▼ (Isophane Insulin Injection (NPH), human insulin (emp)). HUMAN MIXTARD® 30/70 ▼ (Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (emp)). HUMAN INITARD® 50/50 ▼ (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection (NPH), human insulin (emp)). **Presentation** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10 ml. vials containing 100 iu/ml. To aid identification the metal sealing rings of the vials have tactile marks as follows: Human Velosulin – one mark; Human Insulatard – two marks; Human Mixtard 30/70 – three marks; Human Initard 50/50 – four marks. The vials are fitted with tamper-evident caps. **Uses** The treatment of insulin-requiring diabetes. **Dosage and Administration** The dosage of insulin is determined by the physician according to the needs of the patient. Human Velosulin may be given by s.c., i.m., or i.v. injection. Human Insulatard, Human Mixtard 30/70 and Human Initard 50/50 should be re-suspended by inverting the vial several times before being given by s.c. or i.m. injection (they must not be given intravenously). Intermixing does not affect the characteristics of any of these insulins. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Use in the elderly:** Insulin may have a more prolonged action due to reduced clearance rates. **Contra-indications warnings etc. Contra-indications:** Hypoglycaemia. **Precautions:** Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with thyroxine, corticosteroids, oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements. **Side and Adverse Effects:** Hypoglycaemia. Local reactions, lipodystrophy and hypersensitivity reactions are rarely reported with human insulins. **Pharmaceutical Precautions** Store between 2–8°C, protected from sunlight. Insulin which has been frozen should not be used. **Legal Category** P. **Package Quantities** 10 ml. glass vials. **Basic NHS Price** £7.31. **Product Licence Numbers** NORDISK-UK: Human Velosulin 3132/0031; Human Insulatard 3132/0034; Human Mixtard 30/70 3132/0037; Human Initard 50/50 3132/0040. THE WELLCOME FOUNDATION LTD: Human Velosulin 0003/0211; Human Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. Further information is available on request from either: Nordisk-UK, Nordisk House, Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. Tel: East Grinstead (0342) 410373, or Wellcome Medical Division, The Wellcome Foundation Ltd, Crewe Hall, Crewe, Cheshire CW1 1UB. Tel: Crewe (0270) 583151.

Nordisk | Wellcome

Reference 1. Heine R.J. et al, Diabetologia, 1984; 27; 558-562. ®Registered Trade Mark

HUMAN VELOSULIN®

Human neutral soluble insulin (emp)

HUMAN INSULATARD®

Human isophane (NPH) insulin (emp)

Quick and intermediate acting insulins developed to be compatible.

No interaction when mixed.[1]

Predictable effect in individually titrated regimens.